The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

Oct. 17, 2017
Applicant:

Michael J Powell, Alamo, CA (US);

Inventor:

Michael J Powell, Alamo, CA (US);

Assignee:

DIACARTA LTD, George Town, KY;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C12N 15/90 (2006.01); C07H 21/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); C12N 15/907 (2013.01); C07H 21/00 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3517 (2013.01); C12N 2310/3519 (2013.01);
Abstract

The invention provides specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.


Find Patent Forward Citations

Loading…